To support recommendations in its submission, ACP developed the following: a comprehensive review of pharmacist prescribing,[3] The ACP presented the proposed expanded scope of practice to the Minister and the Health Professions Advisory Board in November 2003[8] supported by numerous organizations including the University of Alberta Faculty of Pharmacy, the National Association of Pharmacy Regulatory Authorities (NAPRA), the Pharmaceutical Examining Board of Canada (PEBC) and the Minister of Health and Wellness Enzalutamide molecular weight at that time, Ms Iris Evans. External stakeholders

also presented information to the board at that meeting. Cabinet approved Bill 22 on 30 May 2006 and it was proclaimed in force on 1 April 2007. The following explanatory analysis will describe the development and implementation of Bill 22 to the Health Professions Act (1999). The framework adopted for this analysis is proposed by Lomas,[9] including problem definition, policy development process, and consequences of implementation. There are a number of inter-related problems driving the development of this legislation. The HWRC identified the following

problems, among others: The healthcare system is inefficient because it is not flexible with respect to scopes and roles of practice. More reflective of the time in which Bill 22 was being developed, the 2001 Premier’s Advisory Council on Health for Alberta Report (Mazankowski Report) described five areas within the current healthcare structure that the province needed to address.[10] These are described in Table 1. In a direct mailing to ACP stakeholders Compound C in vitro entitled ‘Pharmacist Prescribing: The Facts’ the perceived problems which Bill 22 would

address, from the perspective of the pharmacist profession, included: Pharmacists are drug-therapy experts who are limited by existing legislation from optimizing their contribution to the healthcare system. Stakeholders who participated directly in the process of developing, or are influenced by, these Regulations are described in Table 2. The ACP[11] proposed that pharmacists be given legislative authority Nintedanib (BIBF 1120) for three activities: 1 Initial prescribing access: Prescribing when a patient chooses the pharmacist for advice and treatment of minor injuries, chronic illnesses or conditions, to support lifestyle changes, disease prevention, or for time sensitive care. For these options presented, an analysis of the knowledge taken into account in formulating this alternative, core values underpinning the policy and the relationship to the goals of the policy is provided in Table 3.[12,13] Table 4 describes the barriers and facilitators for areas of knowledge, key values, institutional structures and external influences.[14–16] Privileges for pharmacists in Alberta granted through this policy include: 1 Initial prescribing access.